Anti-stroke prophylaxis--the ethics of collateral damage.
Prophylactic anticoagulation therapy with agents such as dabigatran etexilate (as an alternative to warfarin) promises substantial benefits to both patients and monitoring physicians in the treatment of those at high risk of stroke from atrial fibrillation. Such treatment has, however, one potentially lethal consequence. There is, as yet, no easily administered rapid means of reversal in instances of acute surgical emergency. The problems that may then be encountered in neurosurgical practice are discussed.